Get the Stockscreener App
19.38
7.09%
-1.48
After Hours:
19.10
-0.28
-1.44%
Hims Hers Health Inc stock is traded at $19.38, with a volume of 22.25M.
It is down -7.09% in the last 24 hours and up +33.47% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$20.86
Open:
$20.58
24h Volume:
22.25M
Relative Volume:
0.71
Market Cap:
$4.42B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
37.12
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
-11.99%
1M Performance:
+33.47%
6M Performance:
-66.82%
1Y Performance:
-39.29%
1-Day Range:
$19.18
$20.60
1-Week Range:
$19.18
$23.10
52-Week Range:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
19.38 | 4.42B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.91 | 56.58B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
113.35 | 47.85B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.80 | 43.75B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.74 | 33.47B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
522.83 | 22.91B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-10-26 | Upgrade | Citigroup | Sell → Neutral |
| Mar-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-24-26 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Hims & Hers Health stock price forecast: persistent bearish setup as HIMS extends decline toward $18 - Traders Union
SG Americas Securities LLC Boosts Stock Position in Hims & Hers Health, Inc. $HIMS - MarketBeat
Barclays raises PT on Hims & Hers Health (HIMS) stock - MSN
Hims & Hers Health Options Spot-On: On March 27th, 145.81K Contracts Were Traded, With 1.12 Million Open Interest - Moomoo
Hims & Hers Stock Decline Amid Legal Battles and Strategic Repositioning - StocksToTrade
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know - Yahoo Finance
TD Cowen Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price - MarketBeat
Hims & Hers Health Launches Offering Featuring Novo Nordisk Products - marketscreener.com
From Breaking Stigma to Building the Future of Health - Hims & Hers Newsroom
Hims & Hers Health | SCHEDULE 13G/A: Others - Moomoo
Hims & Hers expands integrated digital healthcare ecosystem - msn.com
Hims & Hers: The Reset Before The Next Inflection (NYSE:HIMS) - Seeking Alpha
Vanguard (HIMS) reports 0 shares after internal realignment — Schedule 13G/A - Stock Titan
Hims & Hers Health (HIMS) price target decreased by 14.58% to 25.63 - MSN
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Canaccord reiterates Hims and Hers stock rating on Novo launch - Investing.com
Canaccord reiterates Hims and Hers stock rating on Novo launch By Investing.com - Investing.com India
HIMS Forecast, Price Target & Analyst Ratings | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
Oil Surge Past $100, S&P 500 Changes & AI Trends | Market AnalysisNews and Statistics - IndexBox
Hims & Hers shifts business model after Novo deal - thestreet.com
Hims and Hers stock price target maintained at $23 by BofA Securities - Investing.com South Africa
What's Happening With Novo Nordisk Stock Today? - Benzinga
Hims & Hers Health (HIMS) Expands Offerings with Novo Nordisk Me - GuruFocus
-3.50% for Hims & Hers Health stock as daily low tests immediate support - Traders Union
Hims & Hers Health starts selling Novo Nordisk's Wegovy, Ozempic - Seeking Alpha
Why is Hims & Hers Health stock down today? - Traders Union
Hims & Hers adds Novo Nordisk GLP-1 medications to platform - investing.com
Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers - HIMS Investor Relations
Wegovy® Pill and Wegovy® Pen Now Available with Hims & Hers - Hims & Hers Newsroom
It’s Easier Than Ever To Get A Prescription Online. That Might Be A Problem - MedShadow Foundation
HIMS Stock In Spotlight After Hims & Hers Adds Novo’s GLP-1 Treatments To Its Platform - Stocktwits
Hims & Hers Health Options Spot-On: On March 25th, 136.26K Contracts Were Traded, With 1.06 Million Open Interest - Moomoo
Hims & Hers: Distressed Valuations Will Not Last For Long (NYSE:HIMS) - Seeking Alpha
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now? - TradingView
With Legal Overhang Behind, Hims Looks To Drive Growth via Novo Partnership and International Push - Morningstar
Hims & Hers Health stock slips 3.33% as resistance holds and sellers dominate near $20.00 support - Traders Union
HIMS Stock | Hims & Hers Health, Inc. Price, Quote, News & Analysis - TipRanks
Oluyemi Okupe Sells 9,217 Shares of Hims & Hers Health (NYSE:HIMS) Stock - MarketBeat
Hers Review: Is It Right for You? - Healthline
Hims & Hers Faces Multifaceted Challenges as Investor Confidence Wavers - AD HOC NEWS
Okupe, Hims & Hers health CFO, sells $219k in shares - Investing.com
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity - Stock Titan
Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny - MSN
Hims & Hers Faces Legal Scrutiny Over Wegovy Sales - StocksToTrade
Hims & Hers Health Options Spot-On: On March 24th, 116.22K Contracts Were Traded, With 1.04 Million Open Interest - Moomoo
Hims & Hers Health (HIMS) Valuation After Novo Nordisk Weight Loss Deal And Product Exit - Yahoo Finance
INSP vs. HIMS: Which Stock Should Value Investors Buy Now? - Yahoo! Finance Canada
-3.85% for Hims & Hers Health stock as mixed momentum highlights limited upside - Traders Union
Osborne Clarke advises Hims & Hers Health, Inc on the UK, German and Dutch aspects of its acquisition of Eucalyptus - Osborne Clarke
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.11%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):